eFoodSafety.com, Inc. Reports More Scientific Evidence Points Toward Bird Flu Pandemic; Bird Flu Virus Has Gone Global Spreading to over 40 Countries

Business Wire, July 26, 2006

SCOTTSDALE, Ariz. -- Patricia Gruden, President/CEO of eFoodSafety.com, Inc. (OTCBB:EFSF), reported today that the continued spread of Bird Flu outbreaks in new regions causes the increased probability of second stage human-to-human transmission and a global influenza pandemic of the Bird Flu virus according to World Bank reports.

Until recently, the highly pathogenic avian influenza H5N1 virus has been concentrated in East Asia, where about 10 countries had experienced outbreaks since late 2003, with the most serious in Vietnam, Thailand, Indonesia, and China. In the last six to nine months, the virus has gone global, spreading to over 40 more countries.

The World Bank has estimated that a severe avian flu pandemic among humans could cost the global economy about 3.1 percent of the gross domestic product - about US$1.25 trillion on a world gross domestic product of $40 trillion.

"We continue to work diligently with continued testing in the East Asian region, and are working to gain product exposure throughout this territory. In the event of an outbreak, our product's exposure will prove to be very significant in that the regional laboratories will already be familiar with Citroxin and its test results, and eFoodSafety.com, Inc. will subsequently have the ability to forward these results to the appropriate government agencies throughout regions where the outbreak has occurred," stated Mrs. Gruden.

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the TalsynT-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for CinnergenT, a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and TrimmendousT, a weight loss formula focusing on the body's 24-hour metabolic processes. The company has recently entered into a joint venture agreement with CK41 Direct, Inc. to launch an anti-acne skin care system, with a branded name and celebrity spokesperson to-be-announced in the near future.

Please visit the Company's website at: http://www.efoodsafety.com.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.